Asthma treatment and asthma prevention: a tale of 2 parallel pathways

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Clinical Trials Research

Background:

• Asthma development is linked to airway inflammation and structural changes.
• Inhaled corticosteroids (ICS) are effective for managing asthma symptoms.
• The potential for early ICS use to alter asthma's natural course in high-risk infants remains unclear.

Purpose of the Study:

• To evaluate if early introduction of inhaled corticosteroids in high-risk infants and young children can alter the natural course of asthma development.

Main Methods:

• Three distinct clinical trials were conducted with different study designs.
• Participants included infants and young children identified as high-risk for asthma.
• Outcomes were assessed 2-4 years post-randomization, comparing active ICS treatment to placebo.

Main Results:

• No significant differences were observed in treatment requirements between the ICS and placebo groups.
• Symptom frequency off-treatment and lung function did not differ between groups.
• These results indicate early ICS intervention did not alter disease progression over 2-4 years.

Conclusions:

• Early inhaled corticosteroid treatment does not appear to prevent the development of persistent asthma in high-risk children.
• Findings challenge the hypothesis that airway inflammation responsive to ICS is the primary driver of chronic asthma-related airway changes.
• Future asthma prevention strategies require a deeper understanding of genetic, environmental, and developmental factors influencing airway injury responses.